bosentan anhydrous has been researched along with tacrolimus in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Auld, DS; Austin, CP; Huang, R; Moeller, TA; Sakamuru, S; Shinn, P; Shukla, SJ; Vanleer, D; Xia, M | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Soydan, G; Tekes, E; Tuncer, M | 2 |
| Barrientos, A; López-Farré, AJ; Macaya, C; Marques, M; Modrego, J; Rodríguez, P; Segura, A; Zamorano-León, JJ | 1 |
1 review(s) available for bosentan anhydrous and tacrolimus
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
10 other study(ies) available for bosentan anhydrous and tacrolimus
| Article | Year |
|---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Identification of clinically used drugs that activate pregnane X receptors.
Topics: Animals; Cell Line, Tumor; Cytochrome P-450 CYP3A; Drug Interactions; Hep G2 Cells; Hepatocytes; Humans; Pharmaceutical Preparations; Pregnane X Receptor; Rats; Receptors, Steroid; Small Molecule Libraries; Species Specificity; Structure-Activity Relationship; Xenobiotics | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
The role of endothelin in FK506-induced vascular reactivity changes in rat perfused kidney.
Topics: Animals; Bosentan; Dose-Response Relationship, Drug; Endothelin Receptor Antagonists; Endothelins; Immunosuppressive Agents; In Vitro Techniques; Kidney; Male; Mesenteric Arteries; Nitroprusside; Norepinephrine; Perfusion; Rats; Rats, Wistar; Renal Artery; Sulfonamides; Tacrolimus; Vasoconstriction; Vasoconstrictor Agents; Vasodilation; Vasodilator Agents | 2005 |
Short-term and long-term FK506 treatment alters the vascular reactivity of renal and mesenteric vascular beds.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Bosentan; Dose-Response Relationship, Drug; Endothelin A Receptor Antagonists; Endothelin-1; Hypertension; Immunosuppressive Agents; Kidney; Male; Malondialdehyde; Mesentery; Nitroprusside; Norepinephrine; Oxidative Stress; Rats; Rats, Wistar; Receptor, Endothelin A; Sulfonamides; Tacrolimus; Time Factors; Vasoconstriction; Vasoconstrictor Agents; Vasodilator Agents | 2006 |
Changes by tacrolimus of the rat aortic proteome: involvement of endothelin-1.
Topics: Animals; Aorta; Bosentan; Cytoskeleton; Endothelin Receptor Antagonists; Endothelin-1; Energy Metabolism; Gene Expression Regulation; Immunosuppressive Agents; Lamin Type A; Membrane Glycoproteins; NADPH Oxidase 2; NADPH Oxidases; Oxidative Stress; Proteome; Proteomics; Rats; Rats, Inbred WKY; Sulfonamides; Tacrolimus | 2012 |